Letter: Pitavastatin supplementation of PEG-IFN/ribavirin improves sustained virological response against HCV.
Department of Gastroenterology and Metabolism, Applied Life Sciences, Institution of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. d093392@hiroshima-u.ac.jp.
S
S
Yokoyama
Y
Y
Kawakami
K
K
Chayama
D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin